KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Long-Term Deferred Tax: 2009-2024

Historic Long-Term Deferred Tax for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $1.8 billion.

  • Teva Pharmaceutical Industries' Long-Term Deferred Tax fell 21.06% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year decrease of 21.06%. This contributed to the annual value of $1.8 billion for FY2024, which is 0.72% down from last year.
  • According to the latest figures from FY2024, Teva Pharmaceutical Industries' Long-Term Deferred Tax is $1.8 billion, which was down 0.72% from $1.8 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Long-Term Deferred Tax ranged from a high of $1.8 billion in FY2023 and a low of $596.0 million during FY2021.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $1.8 billion (2024), whereas its average is $1.7 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Long-Term Deferred Tax fell by 14.24% in 2021, and later skyrocketed by 144.63% in 2022.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Long-Term Deferred Tax stood at $695.0 million in 2020, then fell by 14.24% to $596.0 million in 2021, then skyrocketed by 144.63% to $1.5 billion in 2022, then grew by 24.28% to $1.8 billion in 2023, then declined by 0.72% to $1.8 billion in 2024.